PURPOSE: The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized. The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab has a broad US Food and Drug Administration label and National Comprehensive Cancer Network guideline level 2b recommendation in this setting; we thus explored our institutional experience in this population. METHODS: We conducted a retrospective analysis of patients with mRCC who were treated with bevacizumab in the second- and/or third-line settings; the primary endpoint was progression-free survival (PFS). Overall response rates (ORR), overall survival (OS), and toxicity were analyzed. RESULTS: Twenty-one patients were treated with bevacizumab: the median age was 63 years old; 80% were white and 14% were black; 80% had clear cell histology. All the patients had prior VEGFR TKI therapy; 43% had prior mTOR inhibitor; the median number of prior therapies was 3. The median PFS was 4.4 months (95% CI, 2.8-9.6 months), and the median OS was 19.4 months (95% CI, 9.9-NR months). ORR was 9.5%; 52% of subjects had stable disease as best response, and 52% had disease progression. For subjects treated with prior VEGF and mTOR inhibitors, median PFS and OS were 4.4 and 13.2 months, respectively. Grade 3 to 4 toxicities included fatigue (29%), dehydration (24%), failure to thrive (10%), constipation (10%), and muscle weakness (10%). CONCLUSIONS: Single-agent bevacizumab has acceptable toxicity and moderate disease-stabilizing activity in selected patients with mRCC who have failed prior VEGFR TKI and mTOR inhibitors. These data support clinical benefit to continued ongoing VEGF inhibition. Further prospective studies of bevacizumab alone or with alternative targeted agents in previously treated populations with mRCC are warranted.
PURPOSE: The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized. The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab has a broad US Food and Drug Administration label and National Comprehensive Cancer Network guideline level 2b recommendation in this setting; we thus explored our institutional experience in this population. METHODS: We conducted a retrospective analysis of patients with mRCC who were treated with bevacizumab in the second- and/or third-line settings; the primary endpoint was progression-free survival (PFS). Overall response rates (ORR), overall survival (OS), and toxicity were analyzed. RESULTS: Twenty-one patients were treated with bevacizumab: the median age was 63 years old; 80% were white and 14% were black; 80% had clear cell histology. All the patients had prior VEGFR TKI therapy; 43% had prior mTOR inhibitor; the median number of prior therapies was 3. The median PFS was 4.4 months (95% CI, 2.8-9.6 months), and the median OS was 19.4 months (95% CI, 9.9-NR months). ORR was 9.5%; 52% of subjects had stable disease as best response, and 52% had disease progression. For subjects treated with prior VEGF and mTOR inhibitors, median PFS and OS were 4.4 and 13.2 months, respectively. Grade 3 to 4 toxicities included fatigue (29%), dehydration (24%), failure to thrive (10%), constipation (10%), and muscle weakness (10%). CONCLUSIONS: Single-agent bevacizumab has acceptable toxicity and moderate disease-stabilizing activity in selected patients with mRCC who have failed prior VEGFR TKI and mTOR inhibitors. These data support clinical benefit to continued ongoing VEGF inhibition. Further prospective studies of bevacizumab alone or with alternative targeted agents in previously treated populations with mRCC are warranted.
Authors: Chung-Han Lee; Andreas M Hötker; Martin H Voss; Darren R Feldman; Kaitlin M Woo; Sujata Patil; Devyn T Coskey; Oguz Akin; James J Hsieh; Robert J Motzer Journal: Clin Genitourin Cancer Date: 2015-08-07 Impact factor: 2.872
Authors: Roberto Pili; Opeyemi Jegede; Michael A Carducci; Judith Manola; David L Groteluschen; Leonard L Appleman; Glenn Liu; James C Shanks; Shaker R Dakhil; Janice Dutcher; Robert S DiPaola Journal: Clin Genitourin Cancer Date: 2017-04-26 Impact factor: 2.872
Authors: Marina Poettler; Matthias Unseld; Kira Braemswig; Andrea Haitel; Christoph C Zielinski; Gerald W Prager Journal: Mol Cancer Date: 2013-12-21 Impact factor: 27.401
Authors: Roberto Pili; Glenn Liu; Sreenivasulu Chintala; Hendrick Verheul; Shabnam Rehman; Kristopher Attwood; Martin A Lodge; Richard Wahl; James I Martin; Kiersten Marie Miles; Silvia Paesante; Remi Adelaiye; Alejandro Godoy; Serina King; James Zwiebel; Michael A Carducci Journal: Br J Cancer Date: 2017-02-21 Impact factor: 7.640
Authors: Thomas Powles; Michael B Atkins; Bernard Escudier; Robert J Motzer; Brian I Rini; Lawrence Fong; Richard W Joseph; Sumanta K Pal; Mario Sznol; John Hainsworth; Walter M Stadler; Thomas E Hutson; Alain Ravaud; Sergio Bracarda; Cristina Suarez; Toni K Choueiri; James Reeves; Allen Cohn; Beiying Ding; Ning Leng; Kenji Hashimoto; Mahrukh Huseni; Christina Schiff; David F McDermott Journal: Eur Urol Date: 2021-03-05 Impact factor: 24.267